Blankenstein; Thomas

Patent Applications and Registrations

Patent applications and USPTO patent grants for Blankenstein; Thomas.The latest application filed is for "cd22-specific t cell receptors and adoptive t cell therapy for treatment of b cell malignancies".

Company Profile

7.11.15

Blankenstein; Thomas - Berlin DE

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
High avidity antigen recognizing constructs Grant 11,447,536 - Blankenstein , et al. September 20, 2	2022-09-20
High avidity HPV T-cell receptors Grant 11,401,316 - Blankenstein , et al. August 2, 2	2022-08-02
Cd22-specific T Cell Receptors And Adoptive T Cell Therapy For Treatment Of B Cell Malignancies App 20220064256 - BLANKENSTEIN; Thomas ; et al.	2022-03-03
T Cell Receptors For Tumor Specific Proteasome Splice Variants And Uses Thereof App 20210061876 - BLANKENSTEIN; Thomas ; et al.	2021-03-04
Combined T cell receptor gene therapy of cancer against MHC I and MHC II-restricted epitopes of the tumor antigen NY-ESO-1 Grant 10,781,243 - Blankenstein , et al. Sept	2020-09-22
Tumor specific T-cell receptors Grant 10,683,336 - Blankenstein , et al.	2020-06-16
High Avidity Antigen Recognizing Constructs App 20190375816 - Blankenstein; Thomas ; et al.	2019-12-12
Novel T Cell Receptors And Immune Therapy Using The Same For The Treatment Of Cancer And Infectious Diseases App 20190359677 - BLANKENSTEIN; Thomas ; et al.	2019-11-28
High avidity antigen recognizing constructs Grant 10,377,808 - Blankenstein , et al. A	2019-08-13
High Avidity Hpv T-cell Receptors App 20190062398 - BLANKENSTEIN; Thomas ; et al.	2019-02-28
Combined T Cell Receptor Gene Therapy Of Cancer Against Mhc I And Mhc Ii-restricted Epitopes Of The Tumor Antigen Ny-eso-1 App 20180057560 - BLANKENSTEIN; Thomas ; et al.	2018-03-01
Multiple Target T Cell Receptor App 20160222080 - KIEBACK; Elisa ; et al.	2016-08-04
High Avidity Antigen Recognizing Constructs App 20150353622 - BLANKENSTEIN; Thomas ; et al.	2015-12-10
Tumor Specific T-cell Receptors App 20150307585 - BLANKENSTEIN; Thomas ; et al.	2015-10-29
Epitope-tag surface expressed proteins and nucleic acids thereof Grant 9,133,264 - Blankenstein , et al. September 15, 2	2015-09-15
Use of Pol III promoters for controlled expression of therapeutic proteins Grant 9,061,058 - Charo , et al. June 23, 2	2015-06-23
Generation Of Antigen Specific T Cells App 20140141026 - Schendel; Dolores Jean ; et al.	2014-05-22
Generation of antigen specific T cells Grant 8,486,694 - Schendel , et al. July 16, 2	2013-07-16
Multiple Target T Cell Receptor App 20110189141 - Kieback; Elisa ; et al.	2011-08-04
Generation of Antigen Specific T Cells App 20100189728 - Schendel; Dolores ; et al.	2010-07-29
Use Of Pol Iii Promoters For Controlled Expression Of Therapeutic Proteins App 20100160416 - Charo; Jehad ; et al.	2010-06-24
Epitope-tag For Surface-expressed Proteins And Uses Thereof App 20100104556 - Blankenstein; Thomas ; et al.	2010-04-29
T Cell Line-Based Packaging Cell Line for the Production of Retroviruses by Enriching of Cd3 Expressing Cells App 20080201791 - Uckert; Wolfgang ; et al.	2008-08-21

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.